Side-by-side analysis of weight-management and metabolic compounds — tirzepatide vs. semaglutide, retatrutide vs. the dual agonists, and the broader incretin class. Comparisons are drawn from published comparative-effectiveness data, not marketing claims, and note each agent's regulatory status.
A patient presents with a BMI of 38, newly diagnosed hypertension, and no personal or family history of medullary thyroid carcinoma. The clinical question — tirzepatide or semaglutide — previously…
Two Drugs, One Question: Which Actually Moves the Needle? A patient walks into a weight management clinic having already tried liraglutide (Victoza/Saxenda) for 52 weeks. They lost 6% of their body…
Tirzepatide reset the weight-loss benchmark in 2022. Three years later the comparative-effectiveness data has caught up, and the answer to "is tirzepatide better than semaglutide for obesity?" is…
Semaglutide vs tirzepatide vs retatrutide: a data-driven comparison of efficacy, side effects, and clinical-trial results, with each agent's regulatory status noted.